Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Management of the Patient with Stable Ischemic Heart Disease and Preserved Left Ventricular Systolic Function

Slide: 20 of 21

Patient Followup: Potential Harms of ARBs

The patient asks you about the adverse effects of taking an ARB.  After reviewing the clinician guide, you inform him that there is only low level evidence available about patients such as himself who are taking an ARB due to intolerable adverse effects from ACEIs. Taking an ARB may increase his risk of what?

Discussion of answers:

A. Correct. There is low level evidence indicating that patients who are intolerant to ACEIs may have a higher risk of hyperkalemia when they start on an ARB.

B. Incorrect. In stable ischemic heart disease patients with preserved LVSF who were started on an ARB due to ACEI intolerance, there was an increased incidence of hyperkalemia compared to the placebo group. 

C. Incorrect. In stable ischemic heart disease patients with preserved LVSF who were started on an ARB due to ACEI intolerance, there was an increased incidence of hyperkalemia compared to the placebo group.

D. Incorrect. In stable ischemic heart disease patients with preserved LVSF who were started on an ARB due to ACEI intolerance, there was an increased incidence of hyperkalemia compared to the placebo group.